Management

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters. - Dr Reddy"s to strengthen domestic biz - Dr Reddy"s plans to launch Lipitor"s generic version in US - Dr Reddy"s develops generic version of Pfizer"s Lipitor - Intermediate trend reversal confirmed - DRL net doubles to Rs 217 cr - Dr Reddy"s forays into transdermal patch segment The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of Nordic Bioscience said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Gold refineries reduce capacity use by 40%
Hit by poor availability of scrap, expensive raw gold imports.
Popular Articles
Modern furniture stores in NY

Porsche to up dealer network by 2010; launches Panamera
Precision Cars, the official importer of Porsche in the country, is planning to increase its dealer network from the current two to six during the next year, a top company official said.

Sensex starts New Year with 20-month high
The markets opened the New Year on a promising note today with the BSE Sensex shutting the shop at a 20-month high at 17,558.73 gaining 94 points, driven by a rally in the auto and metals counters and firm European cues.

© Copyright 2009